Kymera Therapeutics, Inc. $KYMR Position Lifted by Odyssean LLC

Odyssean LLC lifted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 132.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,485 shares of the company’s stock after purchasing an additional 19,664 shares during the quarter. Kymera Therapeutics comprises about 0.6% of Odyssean LLC’s investment portfolio, making the stock its 2nd biggest position. Odyssean LLC’s holdings in Kymera Therapeutics were worth $3,954,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in KYMR. Merck & Co. Inc. acquired a new stake in Kymera Therapeutics in the 2nd quarter worth about $88,544,161,000. Deutsche Bank AG acquired a new position in shares of Kymera Therapeutics during the 2nd quarter valued at about $12,161,000. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Eagle Health Investments LP acquired a new stake in shares of Kymera Therapeutics in the second quarter worth approximately $19,052,000. Finally, BlackRock Inc. acquired a new stake in shares of Kymera Therapeutics in the second quarter worth approximately $635,067,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Barclays upped their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Bank of America lifted their price target on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Mizuho upped their price objective on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Finally, Royal Bank Of Canada lowered Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $125.65.

Kymera Therapeutics Stock Performance

KYMR opened at $126.64 on Wednesday. Kymera Therapeutics, Inc. has a 1 year low of $39.84 and a 1 year high of $130.05. The firm has a 50 day moving average price of $110.92 and a 200 day moving average price of $92.80. The company has a market cap of $10.53 billion, a PE ratio of -39.09 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. During the same period in the previous year, the company posted ($0.95) earnings per share. Kymera Therapeutics’s revenue was up 465.2% compared to the same quarter last year. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director directly owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,587,629 shares of company stock worth $386,183,782. 15.98% of the stock is currently owned by insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.